Adjuvant systemic therapy for intermediate and large gastric gastrointestinal stromal tumors (GISTs): Is there a survival benefit following margin negative surgical resection? - 18/03/20
Abstract |
Background |
The value of adjuvant systemic therapy after margin-negative resection for gastric gastrointestinal stromal tumors (GISTs) remains unclear.
Methods |
The National Cancer Data Base was queried to identify patients undergoing margin negative resections for gastric GISTs >2 cm between 2010 and 2015. Patients were stratified by tumor size (small: 2.1–5 cm, intermediate: 5.1–10 cm, large: >10 cm), histologic grade (low: ≤5 mitoses/50 HPF and high: >5 mitoses/50 HPF), and use of adjuvant therapy. Multivariable cox proportional hazard methods were used to compare overall survival (OS).
Results |
3520 patients met inclusion criteria. Adjuvant therapy was associated with a statistical improvement in OS (86% vs. 76%, p = 0.014) for those with large tumors but had no measurable effect in patients with small or intermediate sized tumors. On multivariable analysis, this association was independent of grade.
Conclusions |
Adjuvant therapy is associated with improved OS for patients with gastric GISTs >10 cm but provides no statistically significant benefit in OS for those with GISTs 2–10 cm
El texto completo de este artículo está disponible en PDF.Resumen |
In an analysis of 3502 patients from the National Cancer Database who underwent margin-negative resection for nonmetastic gastric gastrointestinal stromal tumor (GIST), those who had small (2.1–5 cm) or intermediate (5.1–10 cm) tumors did not achieve any statistically significant benefit in overall survival after receiving adjuvant systemic therapy compared to observation, regardless of tumor grade. However, patients with large (>10 cm) tumors did achieve a statistically significant benefit in overall survival after receiving adjuvant systemic therapy compared to observation.
El texto completo de este artículo está disponible en PDF.Keywords : GIST, Adjuvant therapy, Imatinib, Overall survival
Esquema
Vol 219 - N° 3
P. 436-439 - mars 2020 Regresar al número
Artículo precedente
- Discussion on: Breast cancer risk assessment in patients who test negative for a hereditary cancer syndrome
- C. Breit, E. Ablah, M. Ward, H. Okut, S.D. Helmer, P.L. Tenofsky
- Discussion on: Adjuvant systemic therapy for intermediate and large gastric gastrointestinal stromal tumors (GISTs): Is there a survival benefit following margin negative surgical resection?
- D. Patel, W.Lutfi P. Sweigert, E. Eguia, G. Abood, L. Knab, P.C. Kuo, M.S. Baker
Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.
¿Ya suscrito a @@106933@@ revista ?